Carbapenem Market Size To Reach $5.24 Billion By 2030

Carbapenem Market Growth & Trends

The global carbapenem market size is expected to reach USD 5.24 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 4.78% from 2023 to 2030. The rise in the utilization of carbapenem-based antibiotics, elevated prescription rates of antibiotics, and progress in research and development resulting in the upcoming novel medications; are a few of the factors that are anticipated to propel the growth of the market over the forecast period.

According to an American Lung Association article, published in November 2022, Pneumonia is more prevalent than commonly perceived, leading to over a million hospitalizations and causing more than 50,000 deaths annually. In May 2023, Antabio initiated its Phase I trial by administering the initial dose of antibiotic therapy to healthy volunteers for hospital-acquired infections. The therapy, known as MEM-ANT3310, combines meropenem (MEM) with Antabio's novel broad-spectrum serine beta-lactamase inhibitor, ANT3310. This is fueling the growth of the market over the forecast period.

Moreover, during the pandemic, healthcare systems worldwide faced immense challenges in managing severe cases of COVID-19, especially in ICU settings. Many critically ill COVID-19 patients required advanced medical care, including the use of antibiotics to address secondary bacterial infections. Carbapenems, being potent broad-spectrum antibiotics, were one of the treatment options considered for bacterial co-infections in these patients. Thus, there was a significant impact during the period of the COVID-19 pandemic on the market.

The regulatory framework for pharmaceuticals in North America, particularly in the United States, is well-established and provides a clear pathway for drug approvals. For instance, in August 2022, Brooks Laboratories made an announcement stating that its subsidiary, Brooks Steriscience, has obtained approval from the United States Food & Drug Administration (USFDA) for the product, Meropenem Injection, available in 500mg per vial and 1gram per vial. This product serves as the generic equivalent to Pfizer Inc.'s Merrem Injection.

However, the overuse and misuse of antibiotics, including carbapenems, contribute to the development of antimicrobial resistance (AMR). As bacteria continue to evolve and become resistant to these drugs, their effectiveness in treating infections diminishes, posing a significant challenge for carbapenems and other antibiotics.

 Request a free sample copy or view report summary: Carbapenem Market Report

Carbapenem Market Report Highlights

• Based on drug class, the meropenem segment dominated the market in 2022, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains. Other segment is anticipated to grow at the fastest CAGR rate

• Based on application, the urinary tract infections (UTIs) segment held the largest share of the market in 2022 and is anticipated to grow at the fastest growth rate. UTIs are considered to be the most common bacterial infections across the globe

• Based on the distribution channel, the hospital pharmacies segment dominated the market in 2022 and is anticipated to grow at the fastest CAGR rate owing to the rising prevalence of bacterial infections

• In 2022, North America dominated the market, owing to the presence of major market players, and robust healthcare infrastructure. These are anticipated to boost the market for carbapenem in the region over the forecast period

• Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to the high prevalence of UTIs, growing healthcare spending, and the development of healthcare infrastructure in developing countries like India and China

Carbapenem Market Segmentation

Grand View Research has segmented the global carbapenem market based on drug class, application, distribution channel, and region:

Carbapenem Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Meropenem

• Imipenem

• Etrapenem

• Others

Carbapenem Application Outlook (Revenue, USD Million, 2018 - 2030)

• Urinary Tract Infections

• Bloodstream Infections

• Intra-abdominal Infections

• Pneumonia

• Others

Carbapenem Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Carbapenem Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Carbapenem Market

• Menarini Group

• Pfizer Inc.

• Sun Pharmaceutical Industries Ltd

• Lupin

• Kopran Limited

• Aurobindo Pharma

• Daewoong Pharmaceuticals Co., Ltd.

• Shenzhen Haibin Pharmaceutical Co. Ltd.

• Merck & Co., Inc.

• Venus Remedies Ltd